OSI Pharmaceuticals Inc.

osi pharmaceuticals inc. - All News and Analysis

• OSI Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript

  Seeking Alpha - 2008-10-22

  Question-and-Answer SessionOperator Thank you sir. The Question and Answer Session will be conducted electronically. Operator instructions We will take our first question from Geoffrey Meacham, with JPMorgan. Please go ahead. [Terry - JPMorgan Chase & Co.] Hey, guys. This is Terry calling in...

  Tags: OSI Pharmaceuticals Inc., J.P. Morgan Chase & Co., Call Transcript, Earnings, Therapy, Alenta, Seeking Alpha

• OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript

  Seeking Alpha - 2008-07-23

  Question-and-Answer SessionOperator Operator Instructions We'll go first to Joel Sendek with Lazard Capital Markets. Joel Sendek - Lazard Capital Markets Hi, thanks. My question has to do with the guidance on Tarceva. And I'm wondering what your assumptions are with regard to the split between Ex-US and US for...

  Tags: OSI Pharmaceuticals Inc.

• OSI Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-06

  Earnings Call ExcerptOSI Pharmaceuticals Inc. OSIP Q1 2008 Earnings Call May 06, 2008 5:00 pm ET Executives Kathy Galante - Head of IR and PR Colin Goddard - CEO Mike Atieh - CFO Gabe Leung - EVP and President of Oncology Analysts Terry Coyne - J.P. Morgan Maged Shenouda...

  Tags: OSI Pharmaceuticals Inc.

• OSI Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-02-21

  Earnings Call ExcerptOSI Pharmaceuticals Inc. OSI Q4 2007 Earnings Call February 21, 2008 5:00 pm ET Executives Kathy Galante - Head of IR and PR Colin Goddard - CEO Michael Atieh - CFO Gabe Leung - President of Oncology Analysts Geoff Meacham - JPMorgan Katherine Kim - Banc of...

  Tags: OSI Pharmaceuticals Inc.

• New ratings on Morgan Stanley Dean Witter & Company, Newmont Mining Corp, Utd Surgical Pt, Allegheny Energy Inc, Osi Pharmaceuticals Inc.

  - 2002-09-25

  M2 PRESSWIRE-25 September 2002-StockPickReport.Com: New ratings on Morgan Stanley Dean Witter & Company, Newmont Mining Corp, Utd Surgical Pt, Allegheny Energy Inc, Osi Pharmaceuticals Inc C1994-2002 M2 COMMUNICATIONS LTD RDATE:09252002 StockPickReport.Com (IARD#119079 - http://www.stockpickreport.com/?src=n3) makes these stock...

  Tags: FINANCE, Investment, Morgan Stanley, Newmont Mining Corp., OSI Pharmaceuticals Inc., stock

Additional Resources

• Zacks Analyst Blog Highlights: Royal Dutch Shell, Plc, Amylin Pharmaceuticals Inc., Eli Lilly, OSI Pharmaceuticals, Inc., and NCI Building Systems Inc

  - 2008-12-18

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Royal Dutch Shell, Plc (NYSE: RDS.A), Amylin Pharmaceuticals Inc. (NASDAQ: AMLN),...

• OSI Pharmaceuticals Announces the Appointment of Mr. Pierre Legault as Executive Vice President and Chief Financial Officer

  - 2008-12-16

  MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today the appointment of Mr. Pierre Legault as Executive Vice President, Chief Financial Officer and Treasurer. Mr. Legault has over 16 years of senior management experience in the pharmaceutical industry including several senior positions at Sanofi-Aventis and Aventis, most notably Worldwide...

• OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 4th

  - 2008-11-24

  MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it will host a live webcast of its R&D Analyst Day on Thursday, December 4, 2008 at 12:30 p.m. Eastern Time. The webcast will be hosted by Colin Goddard, Ph.D., Chief Executive Officer, and members of OSI's management team....

• OSI Pharmaceuticals to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008

  - 2008-11-20

  MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Colin Goddard, Ph.D., Chief Executive Officer of OSI Pharmaceuticals, will present at the Piper Jaffray Conference in New York, NY on Tuesday, December 2, 2008 at 8:30 a.m. Eastern Time. Dr. Goddard will discuss the Company's product portfolio and...

• OSI Pharmaceuticals to Present at the Lazard Annual Healthcare Conference on Tuesday, November 18, 2008

  - 2008-11-11

  MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals, will present at the Lazard Conference in New York, NY on Tuesday, November 18, 2008 at 11:25am Eastern Time. Dr. Goddard will provide an overview on the Company's product portfolio...

• Phase III Study Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

  - 2008-11-07

  First EGFR Targeted and Oral Therapy to Improve Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer Following Initial Treatment SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y. -- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a global Phase III study SATURN met its...

• Skin comorbidity agenda launched

  - 2008-11-01

  [ILLUSTRATION OMITTED] BETHESDA, MD. -- The Society for Investigative Dermatology has launched an ambitious multiyear, multidisciplinary research agenda focusing on skin disease comorbidities. Initially, the Co-Morbidities of Skin Disease project will focus on three main areas: dermatotoxicity resulting from the use of cancer drugs; the association...

• EyeGate Pharma Appoints Board Positions

  - 2008-10-22

  EyeGate Pharma, a specialty pharmaceuticalcompany using iontophoresis technology to safely and non-invasively delivertherapeutics to treat serious ocular diseases, today announced the boardappointments of Mr. Paul G. Chaney as Chairman of the Board, and MortonGoldberg, M.D., as Director. Mr. Chaney is currently a consultant atEyetech, which recently spun out of...

• OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results

  - 2008-10-22

  - Reports Earnings of $0.56 Per Share From Continuing Operations - - Tarceva Global Net Sales of $279 Million Up 23% Over The Third Quarter of 2007 - MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today its financial results for the Company's third quarter...

• OSI Pharmaceuticals to Announce Third Quarter Financial Results on October 22, 2008

  - 2008-10-10

  - Conference Call and Webcast to Follow - MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its third quarter 2008 financial results will be released on October 22, 2008, after the markets close. Following the announcement OSI's management will host a live conference call and...

• Zacks Analyst Blog Highlights: The Potash Corporation of Saskatchewan, Inc., Freddie Mac, Fannie Mae, OSI Pharmaceuticals, Inc. and Stoneridge, Inc

  - 2008-10-09

  CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Potash Corporation of Saskatchewan, Inc. (NYSE: POT), Freddie Mac (NYSE:...

• BellwetherReport.com Analyst Opinions on FLEX, OSIP, DNDN and SLXP

  - 2008-10-06

  BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...

• Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

  - 2008-10-06

  SOUTH SAN FRANCISCO, Calif. & MELVILLE, N.Y. -- Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study BeTa Lung evaluating Avastin([R]) bevacizumab in combination with Tarceva([R]) erlotinib in patients with advanced non-small cell lung cancer NSCLC whose disease had progressed following platinum-based chemotherapy...

• Genentech shares drop on drug test

  - 2008-10-06

  Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer. The trial focused on patients...

• OSI Pharmaceuticals Announces Conversion Period for Convertible Notes

  - 2008-10-01

  MELVILLE, N.Y. -- OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its 2% Convertible Senior Notes due 2025 (the "notes") are now convertible at the option of the holders and will remain convertible through December 31, 2008, the last trading day of the current fiscal quarter, as provided for in...

• Incorporated: 1983
• CEO: Dr. Colin Goddard
• Employees: 488